title: Treatment of immune nephropathies with high doses of immunoglobulins.
abstract: The present study presents the results from the application of high doses of gamma-globulin in the treatment of immune (idiopathic and satellite) glomerulopathies.
  
  
  METHODS
  Twenty patients were treated. Of these 12 were with primary chronic glomerulonephritis, 7--with lupus nephritis and 1--with renal amyloidosis. All diagnoses were verified through a renal puncture biopsy. The following therapeutic scheme was used--85 mg/kg/body weight of gamma-globulin was applied intravenously three times a day every other day till reaching a total course dose of 250 mg/kg/body weight. All patients presented with nephrotic syndrome following conventional treatment with corticosteroids, anticoagulants and anti-aggregants. The blood cell count, the serum creatinine, creatinine clearance, 24 h diuresis and level of proteinuria were monitored.
  
  
  CONCLUSIONS
  14 of the patients showed a complete clinical and laboratory remission. Four of them got an incomplete remission with a proteinuria of 2 g/24 h. No positive effect from the treatment was observed in 2 of the patients. All patients with lupus nephritis were influenced positively to a certain extent by the treatment applied. No serious side effects leading to therapy interruption were observed.
  
  
  CONCLUSIONS
  1. The treatment with high doses of immunoglobulin is a good alternative to the pulse immunosuppressive treatment of patients with idiopathic and lupus nephritides, manifested with a nephrotic syndrome and unaffected by a previous conventional immunosuppressive and anticoagulant therapy. 2. The results from the treatment with high doses of immunoglobulin are more pronounced in patients with lupus nephritides, which in turn raises the possibility for an earlier reduction of corticosteroid therapy and avoidance of its side effects. 3. Immunoglobulin therapy is an alternative in the management of nephrotic symptoms in cases with chronic renal failure where an immunosuppressive treatment is irrelevant.
authors.affiliation: Department of Nephrology, Higher Medical Institute, Plovdiv, Bulgaria.
authors.forename: D G
authors.initials: DG
authors.lastname: Nikolov
authors.forename: S M
authors.initials: SM
authors.lastname: Pandeva
authors.forename: E P
authors.initials: EP
authors.lastname: Kumchev
authors.forename: V D
authors.initials: VD
authors.lastname: Tsekov
authors.forename: E E
authors.initials: EE
authors.lastname: Tilkian
authors.forename: E K
authors.initials: EK
authors.lastname: Manev
authors.forename: Z S
authors.initials: ZS
authors.lastname: Tsvetkova
authors.forename: B L
authors.initials: BL
authors.lastname: Anavi
authors.forename: D J
authors.initials: DJ
authors.lastname: Dimitrakov
mesh_terms: D000686:Amyloidosis / Q000188:drug therapy*; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005921:Glomerulonephritis / Q000188:drug therapy*; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy*; D008181:Lupus Nephritis / Q000188:drug therapy*; D016896:Treatment Outcome; D005719:gamma-Globulins / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D005719:gamma-Globulins